Efficacy and safety of oral strontium ranelate for the treatment of knee osteoarthritis: Rationale and design of randomised, double-blind, placebo-controlled trial

Current Medical Research and Opinion

Volumn 28, Issue 4, 2012, Pages 609-610

  Cooper, Cyrus ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

GELATINASE A; GELATINASE B; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 1BETA; OSTEOCLAST DIFFERENTIATION FACTOR; OSTEOPROTEGERIN; SOMATOMEDIN C; STRONTIUM RANELATE;

CARTILAGE CELL; CARTILAGE DEGENERATION; DOWN REGULATION; DRUG EFFICACY; DRUG SAFETY; HUMAN; KNEE OSTEOARTHRITIS; LETTER; NONHUMAN; OSTEOBLAST; SIGNAL TRANSDUCTION;

BONE DENSITY CONSERVATION AGENTS; FEMALE; HUMANS; MALE; ORGANOMETALLIC COMPOUNDS; OSTEOARTHRITIS, KNEE; THIOPHENES;

EID: 84859726263     PISSN: 03007995     EISSN: 14734877     Source Type: Journal    
DOI: 10.1185/03007995.2012.674502     Document Type: Letter

References (5)

1. Tat SK, Pelletier JP, Mineau F, et al. Strontium ranelate inhibits key factors affecting bone remodelling in human osteoarthritic subchondral bone osteoblasts. Bone 2011;49:559-67
2. Reginster JY, Bruyere O, Collette J. Strontium ranelate treatment increases osteoprotegerin serum levels in postmenopausal osteoporotic women. Bone Jan 12. Epub ahead of print. doi:10.1016/j.bone.2011.12.024
3. Gulhan I, Bilgili S, Gunaydin R, et al. The effect of strontium ranelate on serum insulin like growth factor-1 and leptin levels in osteoporotic post-menopausal women: a prospective study. Arch Gynecol Obstet 2008;278:437-41
4. Montaseri A, Busch F. Mobasheri A, et al. IGF-1 and PDGF-bb suppress IL1-β-induced cartilage degradation though down-regulation of NFκB signalling: involvement of Src/PI-3K/AKT pathway. PloS One 2011;6(12) e28663.doi:10.1371/journal.pone.0028663
5. Henrotin Y, Labasse A, Zheng SX, et al. Strontium ranelate increases cartilage matrix formation. J Bone Miner Res 2001;16:299-308 (Pubitemid 32105411)